The geneType Multi-Risk Test has been designed to identify an individual’s risk of developing various common serious diseases.
It identifies the sporadic (non-inherited) risk that accounts for up to 85% of diagnosed cases of diseases that include ovarian cancer, type 2 diabetes, prostate cancer, colorectal cancer, breast cancer and coronary artery disease.
Knowing the risk of developing a disease allows the patient and their healthcare provider to put together a personalised preventive health plan.
As part of the collaboration, the geneType Multi-Risk Test will be implemented in nine Obstetrics and Gynaecology clinics belonging to Siles Health, a company that treats more than 15,000 patients each year.
GTG CEO Simon Morriss said: “Adoption of geneType Multi-Risk Test by Siles Health provides GTG with immediate access to an important and expanding group of patients, with the opportunity to make a significant improvement in their health outcomes.
“This partnership also represents another significant milestone along our pathway, the successful commercialisation of geneType Multi-Risk Tests.”
Siles Health will provide a dedicated in-house genetic counselling service to create personalised preventative pathways for patients that are identified as having a high risk of developing a disease.
The company will also refer patients to physicians that can provide dedicated genetic counselling support.
Siles Health founder Charles Siles said: “geneType Multi-Risk Test is a critical risk identification tool to assist our practice to identify potentially high-risk patients and develop truly actionable, personalised, preventative health plans.”
GTG stated that the partnership deal provides a framework for establishing a consistent standard of care for physicians and patients for the test.